FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerAntibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from Share XFDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerhttps://pharmaphorum.com/news/fda-clears-seagen-genmabs-tivdak-adc-for-cervical-cancer/
In a class first, Merck’s Keytruda extends survival in cervical cancerMerck & Co’s Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live Share XIn a class first, Merck’s Keytruda extends survival in cervical cancerhttps://pharmaphorum.com/news/in-a-class-first-mercks-keytruda-extends-survival-in-cervical-cancer/
Sanofi, Regeneron prep filings for Libtayo in cervical cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a Share XSanofi, Regeneron prep filings for Libtayo in cervical cancerhttps://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/
Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancerSeagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients Share XSeagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancerhttps://pharmaphorum.com/news/seagen-and-genmab-file-trojan-horse-cancer-drug-with-fda/
AI device could be cheaper and more accurate than smear testsUK startup Lancor Scientific has secured funding to launch a medical device that aims to use artificial intelligence Share XAI device could be cheaper and more accurate than smear testshttps://pharmaphorum.com/news/ai-device-could-be-cheaper-and-more-accurate-than-smear-tests/
FDA approves Keytruda in cervical cancerMerck & Co’s blockbuster Keytruda has been approved in advanced second line cervical cancer, becoming the first drug Share XFDA approves Keytruda in cervical cancerhttps://pharmaphorum.com/news/fda-approves-keytruda-cervical-cancer/
